Phase 2 Completed N=44 Diagnostic

Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease

Liver Cancer

Source: ClinicalTrials.gov NCT00543777 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2021

Primary outcomePrimary: Overall Image Quality of Magnetic Resonance Elastography (MRE)

Summary

The goal of this clinical research study is to test the accuracy of magnetic resonance elastogram (MRE) and 2-point dixon magnetic resonance imaging (2PD MRI) using new computer software (called "phase correction algorithm") in patients who might have liver disease.

Outcome Measures

Outcome	Result	p-value
PRIMARY Overall Image Quality of Magnetic Resonance Elastography (MRE)	—	—
SECONDARY Association Between Degrees of Stiffness Measured by MRE in kPa and Histopathological Grades of Fibrosis and Steatohepatitis	—	—
SECONDARY Hepatic Steatosis	22; 5.0	—

Eligibility Criteria

Inclusion Criteria

Group 1. Non-oncologic patients from VAMC in Houston:
Biopsy proven or clinically suspected advanced parenchymal liver disease
Core biopsies obtained within 1-month of MRI/MRE
No treatment affecting the status of liver between MRI/MRE and post-imaging biopsy
Signed consent
Group 2. Oncologic patients at MDACC:
Clinically or radiographically suspected liver damage, hepatic steatosis, hepatitis, hepatic fibrosis or cirrhosis
Surgical or core biopsy scheduled within 4 weeks of MRI/MRE
Signed consent

Exclusion Criteria

Claustrophobia
Contraindications for MRI
Unable to hold a breath
Ascites or other clinical or radiographical signs of portal hypertension

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00543777). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.